Antibody development for treating COVID-19 continues producing positive results, the latest being from Eli Lilly and Co.’s bamlanivimab (LY-CoV-555), which reduced nursing home residents’ risk of contracting symptomatic COVID-19 by 80%, according to new data from its phase III Blaze-2 study. Read More
With worrisome COVID-19 variants cropping up, developers including the likes of Gritstone Oncology Inc. and Vir Biotechnology Inc. continue their efforts to invent new vaccines that may get around the drawbacks of existing shots if they turn up. Read More
DUBLIN – Mina Therapeutics Ltd. is extending its small activating RNA (saRNA) technology into the central nervous system through a partnership with Les Laboratoires Servier SAS that could be worth as much as €220 million (US$266.5 million) in up-front and milestone payments. Read More
LONDON – Remynd NV has extended its series B, raising a further €12 million and bringing the total for the round to €24 million (US$29 million). The new money will fund clinical proof-of-concept trials in the diverse indications of Alzheimer’s disease and diabetes. Read More
One of the side effects of COVID-19 is the acceleration of a shift in health care delivery that is changing how drug and device companies market their products to doctors. There’s no going back to the commercial model where having a sales rep call on a doctor was the way to market a product, Rita Numerof, CEO and co-founder of Numerof & Associates, said during a Jan. 21 webinar on the impact the pandemic has had on drug and device detailing. Read More
In what is claimed as the first co-authored research between regulatory scientists at the U.S. FDA and a commercial manufacturer of organ-on-a-chip devices, CN Bio's Physiomimix system is shown to perform better than the current standard in vitro liver toxicity tests. Read More
The latest global regulatory news, changes and updates affecting biopharma, including: White House orders regulatory freeze; Former CEO pardoned. Read More
BioWorld looks at translational medicine, including: Tau end run prevents memory deficits, but not inflammation; SCLC subtypes have specific vulnerabilities; Turning tsetse fly meal to poison for sleeping sickness control. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Aquestive, Avicanna, Betterlife, Beximco, Codiak, Galapagos, Elpiscience, Intravacc, LG, Mitsubishi Tanabe, Probiogen, Salarius, Trigr, Ubiquigent, VBI, Xbiotech. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Addex, Eubiologics, J&J, Medolife, Menarini, RDIF, Roche, Turn, Ultragenyx. Read More